MTOR and cytomegalovirus infection: Treatment with everolimus (EVL), a mammalian target of rapamycin (mTOR) inhibitor, has shown itself to be effective in reducing CAV progression and CMV infection, and in decreasing CNI-induced nephrotoxicity in combination with mycophenolate mofetil (MMF) (2–5).